PROTECT-ICD Trial: A study targeting prevention of sudden cardiac death in patients who have reduced cardiac function following a myocardial infarct by assessing whether electrophysiologic study to guide prophylactic implantation of an implantable cardioverter-defibrillator (ICD) early following myocardial infarction (first 40 days) will lead to a significant reduction in sudden cardiac death.

Western Sydney Local Health District0 个研究点目标入组 1,058 人开始时间: 2014年1月16日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Participants will be 2-40 days (inclusive) following a myocardial infarct, with impaired left ventricular systolic function (Left Ventricular Ejection Fraction <=40% or at least moderately impaired).

•* Pregnancy;
•* Nursing home resident dependent on one or more activities of daily living;
•* Significant non-cardiac co-morbidity with high likelihood of death within 1 year;
•* Significant psychiatric illnesses that may be aggravated by device implantation or that may preclude regular follow up;
•* Intravenous drug abuse (ongoing);
•* Unresolved infection associated with risk for hematogenous seeding;
•* Pre-existing implantable cardioverter-defibrillator (ICD);
•* Secondary prevention indication for an ICD (i.e. sustained ventricular arrhythmias occurring more than 48 hours after qualifying myocardial infarction);
•* On the heart transplant list;
•* Recurrent unstable angina despite revascularisation (defined as ongoing chest pain or ischemic symptoms at rest or with minimal exertion despite adequate treatment with anti-anginal medications);
•* Congestive heart failure New York Heart Association class IV, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)

发起方